AGP Franklin LLC Makes New Investment in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

AGP Franklin LLC purchased a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 12,058 shares of the company’s stock, valued at approximately $266,000.

Other hedge funds have also made changes to their positions in the company. FMR LLC boosted its position in Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company’s stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares during the period. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock worth $859,935,000 after buying an additional 4,418,961 shares during the last quarter. Todd Asset Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $58,243,000. Raymond James Financial Inc. acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at $38,914,000. Finally, Norges Bank bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth $38,550,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on TEVA. Barclays decreased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Piper Sandler raised their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. UBS Group cut their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Bank of America reduced their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Finally, StockNews.com lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Monday. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Up 0.9 %

Shares of TEVA stock opened at $13.58 on Tuesday. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The stock has a fifty day moving average price of $15.71 and a 200 day moving average price of $17.79. The stock has a market cap of $15.40 billion, a P/E ratio of -9.37, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.